Lipemia: causes, interference mechanisms, detection and management by Nora Nikolac
©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://dx.doi.org/10.11613/BM.2014.008 Biochemia Medica 2014;24(1):57–67 
  57
Abstract
In the clinical laboratory setting, interferences can be a significant source of laboratory errors with potential to cause serious harm for the patient. 
After hemolysis, lipemia is the most frequent endogenous interference that can influence results of various laboratory methods by several mechani-
sms. The most common preanalytical cause of lipemic samples is inadequate time of blood sampling after the meal or parenteral administration of 
synthetic lipid emulsions. Although the best way of detecting the degree of lipemia is measuring lipemic index on analytical platforms, laboratory 
experts should be aware of its problems, like false positive results and lack of standardization between manufacturers. Unlike for other interferen-
ces, lipemia can be removed and measurement can be done in a clear sample. However, a protocol for removing lipids from the sample has to be 
chosen carefully, since it is dependent on the analytes that have to be determined. Investigation of lipemia interference is an obligation of manufac-
turers of laboratory reagents; however, several literature findings report lack of verification of the declared data. Moreover, the acceptance criteria 
currently used by the most manufacturers are not based on biological variation and need to be revised. Written procedures for detection of lipemia, 
removing lipemia interference and reporting results from lipemic samples should be available to laboratory staff in order to standardize the proce-
dure, reduce errors and increase patient safety.
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Analytical interference is a deviation from the true 
value of the analyte caused by presence of some 
endogenous or exogenous substance (1). In the 
clinical laboratory setting, interferences can be a 
significant source of laboratory errors with poten-
tial to cause serious harm for the patient (2). Unlike 
for hemolysis which is recognized as one of the 
leading causes of preanalytical interference (3), in 
the recent literature reports, lipemia is often over-
looked. The overall frequency of lipemic samples 
ranges from 0.5-2.5%, depending on the type of 
hospital and proportion of inpatient and outpa-
tient samples (4-6). Analysis of preanalytical errors 
in our laboratory revealed low frequency of li-
pemic samples (less than 0.5%) (5). However, in the 
outpatient unit, lipemia was the leading cause of 
unsuitable samples with the frequency almost 
4-fold higher than in hospital patients (5). Al-
though certain proportion of the lipemic samples 
in the laboratory originates from various patho-
physiological conditions (e.g. multiple myeloma, 
diabetes mellitus, acute pancreatitis, kidney failure 
or hypothyreosis), some preanalytical factors sig-
nificantly contribute to lipemia. The recognition 
and management of these issues is a major area 
for improvement in order to minimise laboratory 
errors (7,8).
This article presents an overview on preanalytical 
causes of lipemia, mechanisms of action, methods 
of detection, methods of lipemia removal and in-
vestigation of lipemia in interference studies.
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Causes of lipemia
Lipemia is a turbidity of the sample caused by ac-
cumulation of lipoprotein particles. As lipoproteins 
vary in sizes, not all classes contribute equally to 
the turbidity. The largest particles, chylomicrons, 
with sample size of 70-1000 nm, have the greatest 
potential in causing turbidity of the sample. Accu-
mulation of small particles, high density lipopro-
teins (HDL), low density lipoproteins (LDL) and 
small very low density lipoproteins (VLDL) doesn’t 
result with lipemic samples (Figure 1) (9).
The most common preanalytical cause of lipemia 
is inadequate time of blood sampling after the 
meal. In the hospital setting a certain proportion 
of lipemic samples can’t be avoided, since patients 
are admitted to the emergency services in various 
times of the day and various intervals since their 
last meal. However, outpatients that are arriving to 
laboratory for appointed laboratory testing, should 
be properly prepared and fasting prior to blood 
sampling. Some laboratories instruct their patients 
that they should be fasting only for those tests for 
which values will be influenced by food intake, like 
glucose, lipids or calcium. However, even though 
values of a certain parameters will not be changed 
after the meal, postprandial lipemia of the sample 
can be the cause of the laboratory error. Possibly 
the best example for this fact is prothrombin time 
(PT), that can’t be determined by optic agregom-
etry in grossly lipemic samples, even if the meal it-
self doesn’t induce the change in the PT value (10).
Results of a recently published article by Kackov 
and Simundic on outpatient preparation for blood 
sampling, revealed interesting results (11). When 
asked if they were fasting, 93% (140/150) of the 
surveyed patients confirmed. However, when 
asked to explain the meaning of the fasting state, 
only 58 out of 150 patients were able to properly 
identify the fasting state as it is defined in Croatia 
by national recommendations as 12 hours fast af-
ter the last meal (12,13). Most of the 82 patients 
who wrongly believed that their preparation for 
fasting state was adequate, believed that the exact 
time that has to pass since the last meal does not 
matter. In addition, 5 patients believed that at least 
10 hours has to pass and 13 patients believed that 
at least 8 hours has to pass since the last meal prior 
to blood sampling (11).
There is a large heterogeneity in instructions for 
patient preparation for the laboratory testing. 
Based on the results of a recently published article 
by Working Group on the Preanalytical Phase in 
the European Federation of Clinical Chemistry and 
Laboratory Medicine (EFLM), the time that has to 
pass from the last meal varies between countries 
(14). Italian recommendations require that patient 
has to fast for at least 8 hours, while Australian re-
quire up to 10-16 hours fast prior to laboratory 
testing for lipid status. Therefore, Simundic at al. 
propose that effort should be put in harmonisa-
tion of instructions on patient preparation and dis-
semination of that information to both, patients 
and clinicians (14). Patients are not properly in-
formed on how to prepare for laboratory testing, 
general practitioners and nurses do not provide 
enough information and it is usually too late when 
patient comes to laboratory.
In the hospital patients, lipemia can also be caused 
by sampling too soon after administration of 
parenteral lipid emulsions. These preparations (In-
tralipid®, Fresenius Kabi, Germany and Ivelip®, Bax-
ter Healthcare Corporation, Belgium) are used as 
total parenteral nutrition for neonates (15) or pa-
Figure 1. Lipoprotein particle sizes and lipemia.
Lipoproteins that are coloured dark grey cause turbidity of the 
sample. VLDL – very low density lipoproteins (L – large; M - me-
dium; S – small), LDL - low density lipoproteins; HDL - high den-
sity lipoproteins.








27-35 nm35-60 nm60-200 nm
6-12.5 nm20-26 nm
http://dx.doi.org/10.11613/BM.2014.008 Biochemia Medica 2014;24(1):57–67 
  59
Nikolac N. Lipemia interference
tients in intensive care units (16). Recent literature 
findings describe cases of lipemia, which inter-
fered with laboratory analysis, after prolonged use 
of Intralipid as an antidote in lipofilic drugs poison-
ing (17,18). If it is possible, in order to avoid lipemia, 
the sample has to be taken at least 5-6 hours after 
administration of Intralipid (19).
Mechanisms of lipemia interference
Physical and chemical interference
Accumulation of lipoproteins in the patient sam-
ple can interfere with measured analytes by physi-
cal and chemical interactions. This is especially im-
portant in electrophoretic methods. Bossuyt et al. 
have described lipemia interference in capillary 
electrophoresis of serum proteins (20). When ana-
lyzing patient samples with increased concentra-
tion of triglycerides, they detected an abnormal 
morphology of the alpha-2-globulin fraction. They 
have also replicated that finding when spiking na-
tive samples with sample containing high concen-
tration of triglycerides. The peak height correlated 
with the triglyceride concentration suggesting 
that the interference was present in a dose-de-
pendent manner.
Lipemia can also non-specifically interfere in vari-
ous immunoassays. Lipoproteins can interfere with 
antigen-antibody reaction by blocking binding 
sites on antibodies. This can happen even when 
antibodies are bound to a solid surface. Depend-
ing on the nature of the reaction, the interference 
can cause both, falsely elevated or falsely de-
creased result (21).
Interference in spectrophotometric methods
This mechanism is probably the most common 
way in which lipemia affects results of laboratory 
tests. Lipoprotein particles in the sample can ab-
sorb light. The amount of absorbed light is inverse-
ly proportional to the wavelength and decreases 
from 300 to 700 nm, with no specific absorption 
peaks in between (22). Therefore, methods that 
use lower wavelengths are more affected by li-
pemia, because the absorbance is the highest in 
that part of the spectra. Many clinical chemistry 
methods (like alanine aminotranspherase, ALT; as-
partate aminotranspherase, AST; glucose) use re-
action NAD(P)+ ↔ NAD(P)H + H+ as an indicator re-
action for determining concentration or activity of 
the analyte. Since the change of absorbance is 
measured at 340 nm, most of these methods are 
strongly affected by lipemia.
The direction and the magnitude of lipemia inter-
ference in spectrophotometric methods depend 
on the wavelength of the reaction, the direction of 
the reaction (is an indicator reaction measuring in-
crease or decrease of absorbance) and blanking of 
the method (23). It is therefore possible that the di-
rection and the extent of interference will differ 
when comparing different methods for the same 
parameter. This was confirmed in our recently pub-
lished study (24). We have investigated influence 
of Intralipid induced lipemia on several clinical 
chemistry tests using reagents and analytical plat-
forms from three manufacturers (Cobas® 6000 
<c501> by Roche, AU680 by Beckman Coulter and 
Dimension Vista System by Siemens). For some of 
the tested parameters, the direction and the ex-
tent of lipemia interference was similar, e.g. all 
three manufacturers displayed no significant influ-
ence on CRP (C-reactive protein) concentration 
and significant negative influence on measure-
ment of creatinine. However, the results differed 
significantly for bilirubin concentration measure-
ment. Siemens reagent (diazo-reaction) displayed 
strong positive, Roche reagent (DPD - dichloroph-
enyldiazonium tetrafluoroborate) strong negative 
bias, while Beckman Coulter method (also DPD) 
was hardly at all affected by lipemia (24). Other au-
thors have also found differences in extent of li-
pemia interference between different reagents for 
bilirubin determination (25,26). The influence of li-
pemia differs between manufacturers even if the 
same methodology is used. Meany et al. present 
results of significantly different lipemia influence 
on salicilate and acetaminophen concentration 
determination by two manufacturers (Roche Diag-
nostics and Stanbio Laboratories) using the same 
enzymatic methodology (27).
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Non-homogeneity of the sample
For obtaining serum or plasma for analyte meas-
urement, blood needs to be centrifuged. After 
centrifugation, particles distribute according to 
their density: chylomicrons and VLDL particles 
have low density and will therefore be located at 
the top of the tube, forming a distinct layer. Con-
stituents in the plasma distribute between layers 
depending on their polarity: hydrophobic analytes 
are distributed in the lipid phase. Therefore, ana-
lytes soluble in the aqueous phase (small mole-
cules, electrolytes) will not be present in the upper 
part of the tube. When sampling for measurement, 
most analysers obtain sample from the upper part 
of the tube, using sensors to prevent the needle 
from going too deep into the tube. This can result 
with falsely decreased concentration of electro-
lytes and metabolites. The opposite is valid for po-
lar substances (some drugs, like valproic acid or 
steroid hormones). These analytes will accumulate 
in the upper lipid layer, and their concentration 
will be falsely decreased in the lower part of the 
tube.
Volume displacement effect
This mechanism strongly affects concentration of 
electrolytes. The normal plasma consists of ap-
proximately 92% of water and 8% of lipids. In the 
lipemic sample, the proportion of lipid phase in-
creases and can be up to 25%. Analytes that are 
not distributed in the lipid phase (i.e. electrolytes) 
are distributed in the aqueous part of the sample, 
which now accounts for only 75% of the sample. 
Methods that measure concentration of electro-
lytes in the total plasma volume (including the lip-
id phase), like flame photometry or indirect poten-
tiometry, result with falsely decreased concentra-
tion of electrolytes because of the high dilution 
prior to analysis. Multiplying obtained result after 
the measurement to the full plasma volume, re-
sults with an error in electrolyte concentration. 
This effect is noticed at grossly lipemic samples 
(over 17 mmol/L of triglycerides) (28). Methods that 
are measuring concentration of electrolytes only 
in the water phase without dilution (direct poten-
tiometry), measure the true concentration and are 
not affected by lipemia. Results of electrolyte con-
centration measurement are similar by using direct 
and indirect potentiometry, if there is no distur-
bance of the water phase in the sample, the differ-




Visual detection of lipemia in the patient samples 
is still widely used approach, especially in the lab-
oratories with low number of samples. Lipemia 
can be detected visually if the concentration of 
triglycerides in patient sample is over 3.4 mmol/L 
(32). In the full blood samples, visual detection is 
very hard and can be observed at much higher 
concentration of triglycerides (over 11.3 mmol/L) 
(32). Because of that, lipemia of the full blood sam-
ple often remains undetected. This was recently 
demonstrated by Salvagno et al. in a research to 
determine frequency of lipemia in full blood arte-
rial samples received to laboratory for blood gas 
analysis (33). By measuring the lipemic index, they 
have discovered 11% (52/478) of lipemic samples. 
Lipemia of these samples was not detected visual-
ly when samples were analyzed, but only by meas-
uring L Index. Visual detection of lipemia in the se-
rum gives highly heterogeneous results. In our 
study of methods of lipemia detection, we have 
discovered only moderate degree of agreement 
between 6 laboratory technicians in visual detec-
tion of lipemia (Weighted kappa coefficient, Κ = 
0.70 (95% CI = 0.63–0.77) (34). The results might 
even be worse, if a larger number of laboratory 
staff is involved in the process. Moreover, the de-
gree of comparability with automatic detection 
using lipemic index was even lower (Κ = 0.56, 95% 
CI = 0.42–0.69), proving that visual inspection is in-
adequate method for the detection of lipemia in 
the sample (34).
Triglyceride concentration measurement
Some laboratories include triglyceride concentra-
tion measurement in a rough assessment of de-
gree of lipemia. However, this approach also has a 
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few shortcomings. The proportion of triglycerides 
differs among lipoprotein subclasses and ranges 
between approximately 50% in VLDL particles up 
to 85-90% in chylomicrons. Thus, the degree of 
turbidity does not correlate well with the triglycer-
ide concentration. Twomey et al. confirmed this in 
an experiment where they demonstrated a linear 
agreement between triglyceride concentration 
and lipemic index when lipemia was simulated by 
an addition of standardized lipemic emulsion 
(Ivelip) (r2 for Deming regression = 0.9994) (35). 
However, when lipemic index was correlated with 
triglyceride concentrations in patient sample, for 
both, visually turbid and non-turbid sample, the 
agreement was much lower (r2 = 0.2399 and 
0.7795, respectively).
Most reagents for the triglyceride concentration 
measurement use the enzymatic method based 
on glycerol oxidation to dihydroxyacetone phos-
phate. Concentration of triglycerides is propor-
tional to the rate of glycerol oxidation. Therefore, 
an increased amount of glycerol in the sample will 
result with falsely increased concentration of trig-
lycerides. Several cases of pseudo-hypertriglyceri-
demia, because of both, exogenous or endog-
enous accumulation of glycerol, have been de-
scribed in the literature. Speeckaert MM et al. have 
reported a case of patient with high triglyceride 
concentration (11.3 mmol/L) and very low lipemic 
index (36). An increased osmotic gap implied an 
accumulation of the osmotic active molecule and 
patient history revealed excessive intake of beer 
containing large amount of glycerol. In addition, 
there are genetic causes of glycerol accumulation 
like mutations in the glycerol kinase gene causing 
glycerol kinase deficiency (37). In patients with this 
disorder, triglyceride concentration cannot be 
measured accurately using glycerol-based meth-
ods. Although there is a large body of evidence 
that triglyceride concentration measurement is 
not an ideal way of assessing lipemia, it still has 
some useful practical application. De Haene et al. 
have demonstrated an importance of triglyceride 
concentration measurement in combination with 
the lipemic index, since calculation of triglyceride 
to L-index ratio might help in discriminating be-
tween several causes of lipoprotein disorders, ab-
normalities in glycerol and triglyceride metabolism 
and preanalytical errors due to non-fasting state 
(38).
Automatic detection – L-index
Nowadays, most analytical platforms utilize auto-
matic detection and assessment of the degree of 
lipemia. The method is based on dilution of the 
sample in the saline or buffer and measurement of 
spectra in a wide range of wavelengths. As men-
tioned previously, lipemic samples absorb light 
between 300-700 nm. Though overlapping with 
spectra of bilirubin and haemoglobin for measur-
ing icteric and hemolytic index in the lower wave-
lengths area, only lipemic samples absorb light 
around 700 nm, and therefore those wavelengths 
are used to assess the degree of lipemia. Absorb-
ance is proportional to the amount of lipids in the 
sample. There is a still large heterogeneity be-
tween manufacturers in wavelengths used, how-
ever almost all of them use combinations or two or 
more wavelengths. For example, on the AU series 
(former Olympus) Beckman Coulter uses 660/800 
nm, on Cobas series, Roche uses 660/700 nm and 
on Architect platforms Abbott uses several wave-
lengths (510/524; 572/604; 628/660 and 524/804) 
in a calculation of the degree of lipemia.
Advantages of automatic detection are low cost, 
high speed, increased reproducibility and shorten-
ing of turn-around-time. However, there are also 
some disadvantages.
False positive results can occur in the presence of 
sample turbidity that is not caused by accumula-
tion of lipids, but by other molecules. There are 
several articles describing falsely elevated L-index 
with low lipid values in the case when parapro-
teins are present in the sample (39,40). These arti-
cles even emphasise clinical usefulness of lipemia 
index measurement in detecting M-protein in oth-
erwise asymptomatic patients. In addition, a false 
positive result has been observed in the presence 
of a contrast dye (Patient Blue V dye used during 
cancer surgery) (41). In such cases of clinically un-
clear results, unusually high lipid index that is not 
corresponding to the clinical features of the pa-
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tient, an additional visual inspection of the sample 
might help in determining the origin of turbidity.
Another issue regarding automatic detection of li-
pemia is a lack of standardization among manu-
factures in reporting L-index values. Some use 
semi quantitative, while other use almost fully 
qualitative scales. Depending on the platform 
used, Beckman Coulter expresses its results for L-
index from 0 to 5 (10), and Siemens from 1 to 6 (8), 
while Abbott and Roche use continuous scales 
that correspond to the Intralipid concentration 
used in the simulation studies. Both of these ap-
proaches have advantages; semi quantitative scale 
correlates better with the visual inspection of the 
sample, while continuous scale gives a better cor-
relation between the intensity of interference and 
the effect on the measured result. Because of these 
issues, though significantly standardizing intra-
laboratory assessment of lipemia, L-index cannot 
be compared between different manufacturer’s 
platforms and therefore harmonisation is needed 
in this area.
In addition, reagent for determining lipemic index 
is a laboratory reagent like any other, and prior to 
implementation to routine laboratory practise has 
to be validated. A Clinical Laboratory Standards In-
stitute guideline CLSI C56-A (Hemolysis, Icterus, 
and Lipemia/Turbidity Indices as Indicators of In-
terference in Clinical Laboratory Analysis) gives 
detailed instructions of this practise (42). An inter-
nal quality control has to be performed daily. Since 
there are not available commercially samples, a 
laboratory should prepare its own standards of ei-
ther patient lipemic samples or samples spiked 
with synthetic lipid emulsions.
Lipemia removal
In most cases, lipemia can be removed from the 
sample and measurement can be done in a clear 
sample without interferences. There are several 
ways of removing lipids, and laboratory experts 
should carefully choose which one to use depend-
ing on the tests that have to be measured in the 
sample.
Centrifugation
A recommended procedure for treating lipemic 
samples is centrifugation using ultracentrifuge 
which effectively removes lipids and allows meas-
urement of large number of analytes (42,43). How-
ever, due to the high cost, this equipment it is not 
available in a large number of laboratories. Ultra-
centrifuge can obtain forces up to 100,000– 
2.000,000 x g. In his recently published article, 
Dimeski et al. have proven that high speed centri-
fuge with force of 10,000 x g can be almost as effi-
cient as ultracentrifuge in removing lipid layer (44). 
However, centrifuges generating lower forces will 
only be efficient in clearing the sample if the li-
pemia is caused by accumulation of larger parti-
cles, chylomicrons. If lipemia is caused by accumu-
lation of VLDL particles, process is less effective 
and centrifugation has to be repeated several 
times in order to obtain a clear sample.
After centrifugation, a lipid layer on the top of the 
tube is removed and measurement is done in in-
franatant. This approach is, therefore, not accepta-
ble for measurement of hormones, drugs and oth-
er hydrophobic substances, since they will be dis-
tributed in the lipid layer, and measurement in the 
infranatant will cause falsely decreased result.
Extraction
Lipids can be extracted using polar solvents. Some 
laboratories still use manual protocols with poly-
ethylene glycol or cyclodextrin (45), while this prin-
ciple is now utilized in commercially available kits. 
Based on the literature reports, product Lipoclear 
(StatSpin®, Norwood, MA, USA) is widely used. The 
reagent contains non-toxic, non-ionic polymer 
that binds lipids (46). After centrifugation, these 
particles are precipitated at the bottom of the 
tube, and measurement is performed in a clear su-
pernatant. Although this is a very fast and efficient 
way of removing lipids, which does not require any 
special equipment, it still cannot be used for all 
parameters. While manufacturers report that only 
inorganic phosphates have low recovery (47); oth-
er investigators identified several other unaccept-
able analytes in verification studies. Vermeer et al. 
found following parameters to have recovery low-
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er than 85%: GGT – gamma-glutamyltransferase, 
CK-MB – creatine kinase MB isoenzyme and CRP 
(using Beckman Coulter reagents), and therefore 
can’t be measured in the sample after treatment 
with Lipoclear reagent (48). Recovery lower than 
85% was also confirmed for the same parameters 
in a recently published article by Saracevic at al. 
(49). This study additionally revealed unacceptably 
high recovery for troponin T (124.7 and 121.5% for 
300 and 500 mg/dL of added Intralipid concentra-
tion), indicating that Lipoclear cannot be used for 
clearing samples when this parameter has to be 
measured. The reason of such discrepancy be-
tween manufacturer’s declarations and verifica-
tion studies might be that the manufacturer has 
tested the effect of addition of Lipoclear into the 
clear sample, while two mentioned studies per-
formed recovery experiments in the lipemic sam-
ples.
Sample dilution
For analytes distributed in the lipid layer, methods 
that remove lipid fraction are not acceptable. In 
such cases, measurement can be done in a diluted 
patient sample. Sample can be diluted only 
enough to remove the turbidity interference, but 
not too much to make sure that analyte concen-
tration remains within the analytical limits of the 
tested methods (2 or 3 fold). This is probably the 
best approach for measurement of therapeutic 
drugs in lipemic samples.
Interference testing
Interference testing is an obligation of manufac-
turers of laboratory reagents. Influence of interfer-
ing substance can be tested in two ways. The best 
approach would include comparison of the tested 
method with the reference method, i.e. the one on 
which lipemia has no influence. Interference by li-
pemia would then be assessed by comparing re-
sults and calculating bias between two methods. 
However, for lipemic samples, interference-free 
methods are not widely available, therefore inter-
ference of lipemia has to be quantified using dif-
ferent approach. This includes spiking of native 
sample with some interferent, in order to create li-
pemic sample. The interferent is added in in-
creased concentrations and bias calculated for 
each one. The results are presented graphically on 
interferograms, with an increasing concentration 
on the interferent added on the x-axis, and bias in 
comparison to the original result on the y-axis (Fig-
ure 2) (50,51).
The choice of interferent is problematic for lipemic 
samples. Patient lipemic samples or standardized 
solutions containing lipids can be used. Though 
the use of patient sample would better mimic 
pathophysiologically induced lipemia, it is not ide-
al due to heterogeneity of lipemic samples. Such 
study could hardly be replicated, because, though 
sharing the same lipemic index or concentration 
of triglycerides, the composition of lipoprotein 
particles differs in two lipemic samples. It is there-
fore currently recommended to use standardized 
solutions containing lipids of known concentration 
and composition (42,51).
The most widely used product is Intralipid (Fresen-
ius Kabi AB, Uppsala, Sweden). It is an emulsion 
used for intravenous administration as a source of 
calories and essential fatty acids (19). The product 
can be obtained as 10% or 20% solution mixture 
of soybean oil, egg yolk phospholipids and glycer-
ine. Intralipid containes triglycerides of linoleic, 











Reagent 1 Reagent 2 Reagent 3
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0 CONC. 1 CONC. 2 CONC. 3 CONC. 4 CONC. 5
Figure 2. Interferogram – a graphical presentation of interfer-
ence.
Figure presents measurement of interference for three differ-
ent reagents (Reagent 1, Reagent 2 and Reagent 3). Increasing 
concentrations of interferent are presented on x-axis, and mea-
sured bias on y-axis. Dashed lines present criteria of acceptance. 
A point where the full line intercepts the dashed line is highest 
accepted concentration of interferent.
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lem with Intralipid lies in its particle size. Intralipid 
particles range from 200 nm to 600 nm, with mean 
size of 345 nm and are smaller than large chylomi-
crons (up to 1000 nm), and bigger than medium 
and large VLDL particles (35-200 nm). Therefore, 
effects created by addition of Intralipid into the 
sample are not identical with the pathophysiologi-
cally induced lipemia in the patient sample. This 
was first observed over two decades ago, when 
Nanji et al. obtained differences in analyte concen-
tration in quality control samples spiked with In-
tralipid and patient serum containing the same 
concentration of triglycerides (52). Bronhorst et al. 
conducted the methodologically more convincing 
experiment in the year 2004 (53). He has used pa-
tient lipemic samples to determine concentrations 
of several specific proteins: alpha-1-antitripsin, cer-
uloplasmin, haptoglobin, prealbumin and transfer-
rin. The extent of lipemia was determined by 
measurement of L-index on Modular Analytics P 
800 analyzer (Roche). Samples were then ultracen-
trifuged in order to remove lipemia interference. 
The concentrations of ceruloplasmin, prealbumin 
and transferrin were significantly different in the 
cleared samples, indicating strong influence of pa-
tient lipemia on the results of these tests. However, 
when he has recreated lipemic samples of the 
same lipemic index by adding Intralipid solution, 
the concentrations of measured proteins did not 
change significantly. This article is extremely im-
portant in understanding that Intralipid interfer-
ence studies cannot always be transferred to the 
clinical conditions and do not always correlate 
with lipemia in the patient sample. However, since 
in clinical hospitals, especially in the intensive care 
and neonatal units, lipemia of the samples some-
times originates from intravenously applied Intrali-
pid solution, Intralipid spiking studies are still very 
valuable source of information on lipemia interfer-
ence.
As proposed by CLSI guidelines (42,51), manufac-
turers should report to their users a detailed infor-
mation about the interference study: materials 
used for simulation of lipemic samples, interferent 
concentrations, concentrations of measured ana-
lytes and determined bias. If there is no interfer-
ence, the highest tested concentration of interfer-
ent should be declared. If interference is present, 
the lowest concentration of interferent causing a 
significant bias has to be reported. However, there 
is no consensus on what is a significant bias. Manu-
facturers sometimes use value of 2 x standard de-
viation as significant bias, referring to the fact that 
interference is significant if it is larger than the an-
alytical error of the instrument. In addition, many 
studies use intraindividual coefficient of variation 
(CVw), or 0.5 x CVw as desirable specification for im-
precision (54). According to the concept of total er-
ror, allowable bias for interference can be calculat-
ed as I = CVW - (1.96 x CVa) – B; where CVa is an ana-
lytical coefficient of variation, and B is bias of the 
method (55). Depending on the clinical use of the 
laboratory test, the laboratory manager can 
choose each of these concepts, since each of them 
recognizes specificities of particular analyte and 
modifies criteria accordingly. The acceptance crite-
ria for interference will not be the same for the an-
alytes with different biological variation and ana-
lytical performance. A careful consideration and 
expert opinion are required to establish accept-
ance criteria, like done in an article by Steen et al. 
(56). Grunbaum et al. used criteria based on both, 
analytical and biological variation (57). Analytically 
significant changes should always be compared to 
the clinically relevant criteria. It is therefore unac-
ceptable that some manufacturers use arbitrary 
values (10% or 20%) for allowable bias for interfer-
ence for all analytes. This concept of arbitrary val-
ues has been used in the past (1,4), but should now 
be abandoned in favour of evidence based crite-
ria. Arbitrary cut-off values make interpretation of 
results from some studies very difficult. When try-
ing to verify manufacturer’s claims for the Roche 
Cobas 6000 assays regarding lipemia, Ji JZ et al. 
have used the same criteria of acceptance as the 
manufacturer (58). That criterion is 10%. They did 
not confirm all manufacturers’ claims with some 
analytes overrating, and some underrating the li-
pemia influence. However, not only that the crite-
rion used is inadequate, the authors did not report 
the concentrations of measured analytes and the 
exact values of the measured bias, which makes 
their results non-applicable for other readers. 
These issues were also addressed by Szoke et al. in 
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their Letter to the editor emphasizing importance 
of using evidence based criteria based on biologi-
cal variation (59). Therefore, manufacturers should 
revise their current stand on declaring data for in-
terference. They should report data in more de-
tails, with as many information as possible and 
with an acceptance criteria adjusted for the tests 
based on biological variation.
Moreover, manufacturer’s data are not always con-
firmed in a laboratory practise. This was demon-
strated in our previously mentioned article, where 
we have discovered that manufacturer’s claims 
were confirmed only for 11 out of 24 tested ana-
lytes for Beckman Coulter, for 20/23 for Roche and 
16/22 for Siemens. Though appearing that Beck-
man Coulter seriously misreported their data on li-
pemia interference, these results are misleading 
since the other two manufacturers used generally 
larger acceptance criteria (24).
In summary, lipemia interference, though not un-
der the spotlight due to the low frequency, is a sig-
nificant source of laboratory errors. Each laborato-
ry should be aware of the influence that lipemia 
can have on the results of the laboratory tests. A 
verification of manufacturer’s claims should be 
done in a laboratory using evidence based criteria 
of acceptance. In addition, written procedures for 
detection of lipemia, removing lipemia interfer-
ence and reporting results from lipemic samples 
should be available to laboratory staff in order to 
standardize the procedure, reduce errors and in-
crease patient safety. We propose a flowchart for 
management of lipemic samples (Figure 3).
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